About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Chennai Drug Firm to Contribute to the Global Crusade Against Drug-resistant TB

by Gopalan on November 14, 2007 at 3:11 PM
Font : A-A+

Chennai Drug Firm to Contribute to the Global Crusade Against Drug-resistant TB

Shasun, a drug-maker based in Chennai, southern India, has emerged one of the 14 firms brought together by the international drug giant Eli Lilly to fight the drug-resistant TB.

Shasun makes an active ingredient in cycloserine, one of the few treatments available worldwide to treat drug-resistant TB.

Advertisement

"Multiple Drug Resistant (MDR) TB and Extreme Drug Resistance (CDR) TB can't be diagnosed rapidly, so it spreads rapidly - in a worst case scenario, drug resistant TB will completely replace drug susceptible strains. Today only four per cent of the strains are drug-resistant, but the situation could change dramatically, unless timely steps are taken," warned Dr.Mario Ravigilone, Director, WHO's Stop TB campaign.

Senior WHO officials, activists and health workers participated in the World Conference of the International Union Against Tunberculosis and Lung Diseases in Cape Town last week.
Advertisement

Eli Lilly has put together a four-way partnership Shasun and China's Haisun Pharmaceuticals.

The cycloserine manufactured through such a collaboration would be sold to the WHO at a third of the market for distribution in the most affected regions

. Mike Okopski of Eli Lilly, the moving spirit behind the venture, said that technology, formulae, trademarks for cyloserine and capreomycin were transferred over four years by his firm following an appeal by the healthcare NGO Medecins Sans Frontieres (MSF) and the WHO.

Apart from Lilly's Partnership, three other global alliances are also pitching in to use the collective resources of the government, the industry and the academic world to create a pipeline of seven new drugs and three new vaccines.

"Public-private partnerships have caught on to solve the financial aspects, where the uncertainty of the science created a barrier for industry," noted Dr.Georgio Rosigno, CEO of the Foundation for Innovative New Diagnostics (FIND).

But the funding problem still looms large, for the existing regimens are cumbersome and protracted while the TB organism explodes in various forms, leaving researchers panting. "We are back in the pre-antibiotics era. We need new drugs, new diagnostics, new vaccines. We have only half of the budget we need, far from the $ 2 billion needed to roll out our Stop TB campaign," Dr.Raviglione somberly.

Source: Medindia
GPL/P
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Health Benefits of Giloy
Breast Cancer Awareness Month 2021 - It's time to RISE
First-Ever Successful Pig-To-Human Kidney Transplantation
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity AIDS/HIV Signature Drug Toxicity 

Recommended Reading
Plan to Contain Drug Resistant TB Launched-WHO
The WHO warned on Friday that the new drug resistant TB could create an "apocalyptic ......
TB: Drug-resistant Strains Impede Control
The emergence of drug-resistant strains of tuberculosis is threatening global control of the ......
South African Scientists Crack Code of Drug-resistant TB
South African scientists have sequenced the entire genome of a strain of extremely drug-resistant .....
AIDS/HIV
"AIDS is an epidemic disease, a potentially preventable, deadly infection for which there is no cure...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use